MarketCapExport financials
Avadel Pharmaceuticals plc (AVDL)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Avadel Pharmaceuticals plc Income Statement 2024-2008 | AVDL
Brief overview of financial performance at Avadel Pharmaceuticals plc
The figures are compared over a five-year interval. Revenue at Avadel Pharmaceuticals plc moved from $59.2 million in 2019 to $169 million in 2024. The cumulative result was +185.6%, corresponding to roughly 23.4% per year. Revenue growth reflects a pronounced phase of business expansion.
Gross profit changed from $47.1 million to $154 million (+226.7%). Revenue outpaced cost of revenue, allowing more sales to flow into gross profit. The gross margin was 79.5% at the start and 91% at the end. A wider margin shows that the economics of the core business improved.
The five-year EBITDA result moved by −148.1%: from −$16 million to −$39.7 million. EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin moved from −27% to −23.5%. The company improved its ability to convert sales into EBITDA.
The net financial result changed from −33.2 million dollars to −48.8 million dollars. The negative result deepened, showing weaker final efficiency.
The five-year change in capitalization reached +163.1%: from 273 million dollars to 717 million dollars. The valuation may already include demanding future expectations.
Conclusion
Positive developments coexist with areas of weakness. The strongest signals are positive operating leverage, sales growth and better sales economics. Caution is warranted because of a low EBITDA margin and a weaker final result. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement Avadel Pharmaceuticals plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
717 M | 1.03 B | 561 M | 472 M | 387 M | 273 M | 103 M | 445 M | 377 M | 412 M | 521 M | 276 M | 103 M | 154 M | - | - | - |
Shares |
95.1 M | 80.2 M | 60.1 M | 58.5 M | 53 M | 37.4 M | 37.3 M | 40.5 M | 41.2 M | 40.6 M | 36.2 M | 25.4 M | 25.1 M | 24.7 M | 24.4 M | 24.2 M | - |
Historical Prices |
7.54 | 12.8 | 9.34 | 8.06 | 8.04 | 9.99 | 1.93 | 8.31 | 10.7 | 8.73 | 15.7 | 10 | 3.95 | 6.39 | - | - | - |
Net Income |
-48.8 M | -160 M | -137 M | -77.3 M | 7.03 M | -33.2 M | -95.3 M | 68.3 M | -41.3 M | 40.7 M | -84.9 M | -42.9 M | -3.23 M | -8.77 M | -8.98 M | -11.4 M | - |
Revenue |
169 M | 28 M | - | - | 22.3 M | 59.2 M | 103 M | 173 M | 150 M | 173 M | 14.8 M | 22.4 M | 26.1 M | 32.6 M | - | - | - |
Cost of Revenue |
15.3 M | 846 K | - | - | 5.74 M | 12.1 M | 17.5 M | 16.3 M | 13.2 M | 11.4 M | 3.38 M | 562 K | 400 K | 6.28 M | 6.91 M | -10.1 M | - |
Gross Profit |
154 M | 27.1 M | - | - | 16.6 M | 47.1 M | 85.8 M | 157 M | 137 M | 162 M | 11.4 M | 18.1 M | 20.2 M | 26.3 M | - | - | - |
Operating Income |
-42.4 M | -138 M | -98.6 M | -85.5 M | 5.82 M | -24.1 M | -105 M | 89.5 M | -4.96 M | 70.8 M | -93.7 M | -53.7 M | -9.91 M | -9.58 M | -9.84 M | -11.8 M | - |
Interest Expense |
- | - | - | - | 13 M | 12.5 M | 1.9 M | 2.07 M | -6.55 M | -4.88 M | 5.75 M | 2.6 M | 118 K | 73 K | 24 K | 100 K | - |
EBITDA |
-39.7 M | -136 M | -97.1 M | -84.7 M | -36.3 M | -16 M | -53.9 M | 64.7 M | 58.2 M | 115 M | -21.6 M | -18.8 M | -16.8 M | -6.24 M | -5.14 M | -5.84 M | - |
Operating Expenses |
196 M | 165 M | 98.6 M | 85.5 M | 53.3 M | 63.9 M | 146 M | 95.9 M | 92.7 M | 59.9 M | 44.7 M | 40 M | 40.3 M | 35.9 M | - | - | - |
General and Administrative Expenses |
181 M | 152 M | 74.5 M | 68.5 M | 32.4 M | 30.2 M | 100 M | 58.9 M | 44.2 M | 21.7 M | 15.7 M | 13.3 M | 14.2 M | 10.8 M | 11.3 M | -13.3 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Avadel Pharmaceuticals plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q4 | 2009-Q4 | 2008-Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
97.1 M | 96.7 M | 96.6 M | 96.5 M | 96.3 M | 96.2 M | 91.7 M | 89.8 M | 89.4 M | 77.2 M | 63.9 M | 62.9 M | 60.2 M | 59 M | 58.8 M | 58.6 M | 58.6 M | 58.5 M | 58.4 M | 58.4 M | 58.2 M | 54.3 M | 41.1 M | 37.5 M | 37.4 M | 37.4 M | 37.4 M | 37.3 M | 36.9 M | 36.8 M | 38.6 M | 37.3 M | 40.1 M | 41.1 M | 41.4 M | 41.4 M | 41.2 M | 41.2 M | 41.2 M | 41.2 M | 40.6 M | 40.4 M | 40.2 M | 40.2 M | 38.8 M | 38.4 M | 28.3 M | 25.6 M | 25.5 M | 25.4 K | 25.4 M | 25.4 M | 25.2 M | 25.2 M | 25 M | 25 M | - | 24.6 K | 24.6 M | 24.4 M | 24.2 M | - |
Net Income |
20 K | 9.66 M | -4.92 M | - | -2.62 M | -13.8 M | -27.3 M | - | -36.3 M | -64.4 M | -30.8 M | - | -20.1 M | -63.4 M | -26.4 M | - | -22 M | -19.6 M | -13.4 M | - | -11.7 M | 30.9 M | -865 K | - | -8.86 M | -8.6 M | -13 M | - | -15.8 M | -3.44 M | -12.2 M | - | 21.7 M | 28.9 M | 25.9 M | - | -20 M | -20 M | -6.06 M | - | -28.1 M | -16.9 M | 11.6 M | - | -10 M | -21.1 M | -26.6 M | - | -6.37 M | -32.9 M | -8.83 M | - | -6.42 M | -5.92 M | 12 K | - | - | -3.46 M | -4.93 M | -8.98 M | -11.4 M | - |
Revenue |
77.5 M | 68.1 M | 52.5 M | - | 50 M | 41.5 M | 27.2 M | - | 7.01 M | 1.5 M | - | - | - | - | - | - | - | - | - | - | - | 10.1 M | 12.2 M | - | 14.2 M | 17.6 M | 16.4 M | - | 19.8 M | 29.2 M | 33.3 M | - | 39.7 M | 46.3 M | 52.5 M | - | 32.1 M | 38.9 M | 36.2 M | - | 47.3 M | 48.6 M | 32.7 M | - | 7.03 M | 4.32 M | 4.58 M | - | 5.58 M | 5.54 M | 5.14 M | - | 5.4 M | 6.03 M | 7.36 M | - | - | 6.75 M | 6.76 M | - | - | - |
Cost of Revenue |
7.83 M | 6.37 M | 5.58 M | - | 6.16 M | 2.79 M | 1.52 M | - | 117 K | 36 K | - | - | - | - | - | - | - | - | - | - | - | 3.28 M | 2.46 M | - | 2.82 M | 3.62 M | 3.27 M | - | 3.12 M | 3.51 M | 6.59 M | - | 3.79 M | 4.56 M | 3.9 M | - | 2.84 M | 3.91 M | 3.91 M | - | 2.09 M | 2.76 M | 3.63 M | - | 1.91 M | 507 K | 773 K | - | 1.74 M | 1.28 M | 995 K | - | 1.5 M | 1.55 M | 1.32 M | - | - | 1.93 M | 1.37 M | 6.91 M | -10.1 M | - |
Gross Profit |
81.6 M | 61.8 M | 46.9 M | - | 43.9 M | 38.7 M | 25.7 M | - | 6.9 M | 1.46 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
1.94 M | 8.88 M | -3 M | - | -327 K | -12.7 M | -26 M | - | -35.1 M | -49.5 M | -28.3 M | - | -17 M | -29.9 M | -28.6 M | - | -25.7 M | -21.9 M | -14.8 M | - | -13.7 M | 40.3 M | -6.5 M | - | -4.15 M | -4.45 M | -8.17 M | - | -14.1 M | -2.78 M | -12.6 M | - | 26.1 M | 34.1 M | 33.3 M | - | -16.2 M | -11.5 M | 5.7 M | - | -14.5 M | -2.37 M | 10.2 M | - | -16.8 M | -19.4 M | -24.2 M | - | -6.8 M | -34.4 M | -9.85 M | - | -6.52 M | -6.33 M | -46 K | - | - | -3.66 M | -4.89 M | -9.84 M | -11.8 M | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -125 K | -310 K | - | -139 K | -50 K | -307 K | - | 425 K | 1.4 M | -395 K | - | 768 K | 1.67 M | 550 K | - | -1.83 M | -2.77 M | -1.53 M | - | - | 310 K | 141 K | - | - | 123 K | 5.55 M | - | - | - | - | - | - | - | - | - | - | - | - | 24 K | 100 K | - |
EBITDA |
4.94 M | 10.8 M | -2.18 M | - | - | - | -25.5 M | - | - | - | -27.7 M | - | -16.1 M | -29.4 M | -28.4 M | - | -25 M | -21.5 M | -14.6 M | - | -12.4 M | 41.2 M | -6.04 M | - | -2.46 M | -3.39 M | -7.8 M | - | -8.47 M | 1.02 M | -10.6 M | - | 28.8 M | 35.7 M | 34.2 M | - | -4.64 M | -3.86 M | 9.46 M | - | -4.69 M | 4.16 M | 13.5 M | - | -13.9 M | -16.5 M | -20.7 M | - | -6.8 M | -34.4 M | -9.03 M | - | -6.52 M | -6.33 M | 662 K | - | - | -3.66 M | -3.86 M | -5.14 M | -5.84 M | - |
Operating Expenses |
79.6 M | 52.9 M | 49.9 M | - | 44.2 M | 51.5 M | 51.7 M | - | 42 M | 51 M | 28.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
52.6 M | 48.6 M | 45.6 M | - | 40.4 M | 47.4 M | 48.6 M | - | 39.2 M | 46.8 M | 24.5 M | - | 14.1 M | 21.8 M | 21.6 M | - | 21.3 M | 15.2 M | 11 M | - | 8.42 M | 7.1 M | 7.91 M | - | 5.32 M | 6.76 M | 10.4 M | - | 24.8 M | 27.8 M | 24.5 M | - | 11.6 M | 12.4 M | 11.8 M | - | 12.7 M | 11.3 M | 9.46 M | - | 4.57 M | 5.87 M | 4.46 M | - | 4.1 M | 4.06 M | 3.52 M | - | 2.92 M | 2.71 M | 2.49 M | - | 3.11 M | 2.91 M | 5.18 M | - | - | 2.53 M | 2.53 M | 11.3 M | -13.3 M | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Avadel Pharmaceuticals plc (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
USA
Irlanda
Canada
China
Schweden
